natgillin/translations-raw huggingface dataset:
In patients with decompensated liver disease, lamivudine should always be used in combination with a second agent, without cross-resistance to lamivudine, to reduce the risk of resistance and to achieve rapid viral suppression.
Pri bolnikih z dekompenzirano jetrno boleznijo, se mora lamivudin vedno uporabljati v kombinaciji z drugim zdravilom, ki nima navzkrižne odpornosti z lamivudinom, da se zmanjša tveganje za odpornost ter da se doseže hitro zaustavitev virusne okužbe.
In patients with delayed graft function, sirolimus may delay recovery of renal function.
Pri bolnikih z upočasnjenim delovanjem presadka lahko sirolimus zapozni okrevanje ledvičnega delovanja.
In patients with delayed graft function, sirolimus may delay recovery of renal function.
Pri bolnikih z upočasnjeno funkcijo presadka lahko zaradi sirolimusa pride do zakasnjenega okrevanja ledvičnega delovanja.
In patients with delayed renal graft function post-transplant, mean MPA AUC (0–12 h) was comparable to that seen in post-transplant patients without delayed graft function.
Pri bolnikih z zapoznelim delovanjem ledvičnega presadka je bila srednja AUC (0–12 ur) mikofenolne kisline primerljiva s tisto pri bolnikih brez zapoznelega delovanja ledvičnega presadka.
In patients with delayed renal graft function post-transplant, mean MPA AUC (0–12h) was comparable to that seen in post-transplant patients without delayed graft function.
Pri bolnikih z zapoznelim delovanjem ledvičnega presadka je bila srednja AUC (0-12 ur) mikofenolne kisline primerljiva s tisto pri bolnikih brez zapoznelega delovanja ledvičnega presadka.
In patients with detectable EGFR protein expression (indicated patient population), overall survival was statistically significantly improved in the Portrazza+GC Arm as compared to the GC Arm with an estimated reduction in risk of death of 21% (hazard ratio [HR] = 0.79 [0.69, 0.92]; p = 0.002) and a median OS of 11.7 months in the Portrazza+GC Arm and 10.0 months in the GC Arm.
Pri bolnikih z izraženostjo beljakovine EGFR (zadevna populacija bolnikov) se je celokupno preživetje statistično pomembno izboljšalo v skupini Portrazza+GC v primerjavi s skupino GC z ocenjenim zmanjšanjem tveganja smrti za 21 % (razmerje tveganja [HR] = 0,79 [0,69; 0,92]; p = 0,002) in mediano celokupnega preživetja 11,7 mesecev v skupini Portrazza+GC in 10,0 mesecev v skupini GC.
In patients with diabetes mellitus optimised glycaemic control delays the onset of late diabetic complications.
Cim boljša glikemicna urejenost pri bolnikih z diabetesom mellitusom odloži nastanek poznih diabeticnih zapletov.
In patients with dry eye disease, a condition that may be considered to have an inflammatory immunological mechanism, following ocular administration, ciclosporin is passively absorbed into T- lymphocyte infiltrates in the cornea and conjunctiva and inactivates calcineurin phosphatase.
Pri bolnikih s sindromom suhega očesa, stanja, za katerega se meni, da ima vnetni imunološki mehanizem, se ciklosporin po dajanju v oko pasivno absorbira v infiltrate T-limfocitov v roženici in veznici in inaktivira kalcinevrin.
In patients with EBC eligible for neoadjuvant-adjuvant treatment, Herceptin should be used concurrently with anthracyclines only in chemotherapy-naive patients and only with low-dose anthracycline regimens i.e. maximum cumulative doses of doxorubicin 180 mg/m2 or epirubicin 360 mg/m2.
Pri bolnikih z zgodnjim rakom dojk, ki so primerni za neoadjuvantno-adjuvantno zdravljenje, se zdravilo Herceptin uporablja sočasno z antraciklini le pri bolnikih, ki še niso bili zdravljeni s kemoterapijo, in to samo pri shemah z majhnimi odmerki antraciklinov (največji kumulativni odmerek doksorubicina 180 mg/m2 ali epirubicina 360 mg/m2).
In patients with EBC eligible for neoadjuvant-adjuvant treatment, Herceptin should be used concurrently with anthracyclines only in chemotherapy-naive patients and only with low-dose anthracycline regimens, i.e., with maximum cumulative doses of doxorubicin 180 mg/m2 or epirubicin 360 mg/m2.
Pri bolnikih z zgodnjim rakom dojk, ki so primerni za neoadjuvantno-adjuvantno zdravljenje, se zdravilo Herceptin uporablja sočasno z antraciklini le pri bolnikih, ki še niso bili zdravljeni s kemoterapijo, in to samo pri shemah z majhnimi odmerki antraciklinov (največji kumulativni odmerek doksorubicina 180 mg/m2 ali epirubicina 360 mg/m2).
In patients with either HBeAg positive or HBeAg negative CHB, the development of YMDD (tyrosine-methionine-aspartate-aspartate) mutant HBV may result in a diminished therapeutic response to lamivudine, indicated by a rise in HBV DNA and ALT from previous on-treatment levels.
Pri bolnikih s HBeAg-pozitivnim ali HBeAg-negativnim kroničnim hepatitisom B lahko pojav YMDD (tirozin-metionin-aspartat-aspartat) mutanta HBV zmanjša terapevtski odziv na lamivudin; to se kaže s porastom HBV-DNA in ALT v primerjavi s predhodnimi ravnmi med zdravljenjem.
In patients with end-stage renal disease (ESRD) requiring haemodialysis, between dialysis drug exposures substantially increased over 72 hours to 53 µg•h/ml (19%) of emtricitabine, and over 48 hours to 42,857 ng•h/ml (29%) of tenofovir.
Pri bolnikih s končno fazo ledvične bolezni (end-stage renal disease – ESRD), pri katerih je potrebna hemodializa, se je izpostavljenost zdravilu med dializami močno povečala v obdobju 72 ur na 53 µg•h/ml (19 %) emtricitabina, v obdobju 48 ur pa na 42,857 ng•h/ml (29 %) tenofovirja.
In patients with ESRD on haemodialysis, approximately 30% of the emtricitabine dose was recovered in dialysate over a 3 hour dialysis period which had been started within 1.5 hours of emtricitabine dosing (blood flow rate of 400 ml/min and dialysate flow rate of approximately 600 ml/min).
Pri bolnikih z ledvičnim obolenjem v zadnji fazi (ESRD, end-stage renal disease) na hemodializi je bilo približno 30 % odmerka emtricitabina pridobljenega v dializatu po 3 urah dialize, s katero je bolnik začel v roku 1,5 ure po uporabi emtricitabina (pretok krvi je 400 ml/min in pretok dializata je približno 600 ml/min).
In patients with existing cardiovascular risk factors, substitution therapy with factor VIII may increase the cardiovascular risk.
Pri bolnikih z obstoječimi dejavniki srčno-žilnega tveganja lahko nadomestno zdravljenje z zdravilom s faktorjem VIII poveča srčno-žilno tveganje.
In patients with existing cardiovascular risk factors, substitution therapy with FVIII may increase the cardiovascular risk.
Pri bolnikih z obstoječimi kardiovaskularnimi dejavniki tveganja lahko nadomestno zdravljenje s FVIII poveča kardiovaskularno tveganje.
In patients with factor VII deficiency, where the recommended dose is 15 – 30 µg/kg rFVIIa, one episode of overdose has been associated with a thrombotic event (occipital stroke) in an elderly (> 80 year) male patient treated with 10 – 20 times the recommended dose.
Pri bolnikih s pomanjkanjem faktorja VII, pri katerih je priporočeni odmerek 15–30 µg/kg rFVIIa, je bilo eno preveliko odmerjanje povezano s trombotičnim dogodkom (okcipitalna kap) pri starejšem (> 80 let) moškem, ki je dobil 10- do 20-kraten priporočeni odmerek.
In patients with flushing, the majority had flushing events that were mild or moderate in severity.
Pri večini bolnikov, pri katerih se je vročinsko oblivanje pojavljalo, so bili dogodki vročinskega oblivanja blagi ali zmerni.
In patients with giant cell tumour of bone, an injection of 120 mg under the skin is given on days 1, 8 and 15 of a four week cycle, and then once every four weeks.
Bolniki z gigantocelularnim kostnim tumorjem prejmejo injekcijo v podkožje v odmerku 120 mg, in sicer prvi, osmi in 15. dan v štiritedenskem ciklu, nato pa enkrat vsake štiri tedne.
In patients with giant cell tumour of bone, Xgeva was effective in controlling the disease.
Pri bolnikih z gigantocelularnim kostnim tumorjem je bilo zdravilo učinkovito pri obvladovanju bolezni.
In patients with gout since low doses of ASA increase urate concentrations.
Pri bolnikih s protinom, ker majhni odmerki ASA povečujejo koncentracijo urata.
In patients with granulomatosis with polyangiitis (Wegener’s) or microscopic polyangiitis, methylprednisolone given intravenously for 1 to 3 days at a dose of 1000 mg per day is recommended prior to the first infusion of MabThera (the last dose of methylprednisolone may be given on the same day as the first infusion of MabThera).
Pri bolnikih z granulomatozo s poliangiitisom (Wegenerjevo granulomatozo) ali mikroskopskim poliangiitisom je pred prvo infuzijo zdravila MabThera priporočljiva intravenska uporaba metilprednizolona, ki se ga daje od 1 do 3 dni v odmerku 1000 mg na dan (zadnji odmerek metilprednizolona je lahko uporabljen na dan prve infuzije zdravila MabThera).
In patients with granulomatosis with polyangiitis or microscopic polyangiitis, the number of peripheral blood B cells decreased to <10 cells/μL after two weekly infusions of rituximab 375 mg/m2, and remained at that level in most patients up to the 6 month timepoint.
Pri bolnikih z granulomatozo s poliangiitisom in mikroskopskim poliangiitisom se je število perifernih celic B zmanjšalo na < 10 celic/µl po dveh infundiranjih 375 mg/m2 rituksimaba (po enem na teden) in je na tej ravni ostalo do 6 mesecev.
In patients with haemophilia type A and B, there have been reports of increased bleeding while taking protease inhibitors.
Pri bolnikih s hemofilijo tipa A in B so med jemanjem zaviralcev proteaz poročali o hujših krvavitvah.
In patients with HBeAg negative CHB (pre-core mutant) without cirrhosis, treatment should be administered at least until HBs seroconversion or there is evidence of loss of efficacy.
Pri HBeAg negativnih (pre-core mutanta) bolnikih s CHB brez ciroze je treba zdravljenje nadaljevati vsaj do HBs serokonverzije ali do pojava znakov izgube učinkovitosti.
In patients with HBeAg negative CHB (pre-core mutant) without cirrhosis, treatment should be administered at least until HBs seroconversion or there is evidence of loss of efficacy. .
Pri HbeAg-negativnih (pre-core mutanta) bolnikih s kroničnim hepatitisom B brez ciroze je treba zdravljenje nadaljevati vsaj do HBs serokonverzije ali do pojava znakov izgube učinkovitosti.
In patients with HBeAg negative CHB (pre-core mutant), without cirrhosis, treatment should be administered at least until HBs seroconversion or there is evidence of loss of efficacy.
Pri HBeAg negativnih (pre-core mutanta) bolnikih s CHB brez ciroze je treba zdravljenje nadaljevati vsaj do HBs serokonverzije ali do pojava znakov izgube učinkovitosti.
In patients with HBeAg positive chronic hepatitis B (CHB) without cirrhosis, treatment should be administered for at least 6-12 months after HBeAg seroconversion (HBeAg and HBV DNA loss with HBeAb detection) is confirmed, to limit the risk of virological relapse, or until HBsAg seroconversion or there is loss of efficacy (see section 4.4).
Pri HBeAg pozitivnih bolnikih s kroničnim hepatitisom B (CHB) brez ciroze mora zdravljenje trajati še vsaj 6-12 mesecev po potrditvi serokonverzije HBeAg (izginotje HBeAg in HBV DNA ter detekcija HBeAb) v dveh zaporednih vzorcih seruma z vsaj 3-mesečnim vmesnim presledkom, da se omeji tveganje virusnega relapsa, ali do serokonverzije HbsAg ali pa se zmanjša učinkovitost (glejte poglavje 4.4).
In patients with HBeAg positive chronic hepatitis B (CHB) without cirrhosis, treatment should be administered for at least 6-12 months after HBeAg seroconversion (HBeAg and HBV DNA loss with HBeAb detection) is confirmed, to limit the risk of virological relapse, or until HBsAg seroconversion or there is loss of efficacy (see section 4.4).
Pri HBeAg pozitivnih bolnikih s kroničnim hepatitisom B (CHB) brez ciroze mora zdravljenje trajati še vsaj 6-12 mesecev po potrditvi serokonverzije HBeAg (izginotje HBeAg in HBV DNA ter detekcija HBeAb), da se omeji tveganje virusnega relapsa, ali do serokonverzije HBsAg ali pa se zmanjša učinkovitost (glejte poglavje 4.4).
In patients with HBeAg positive chronic hepatitis B (CHB) without cirrhosis, treatment should be administered for at least 6-12 months after HBeAg seroconversion (HBeAg and HBV DNA loss with HBeAb detection) is confirmed, to limit the risk of virological relapse, or until HBsAg seroconversion or there is loss of efficacy (see section 4.4).
Pri HbeAg-pozitivnih bolnikih s kroničnim hepatitisom B (CHB), brez ciroze, mora zdravljenje trajati še vsaj šest do dvanajst mesecev po potrditvi serokonverzije HBeAg (izginotje HBeAg in HBV DNA ter detekcija HBeAb), da se omeji tveganje virusnega relapsa, ali do serokonverzije HBsAg ali pa se zmanjša učinkovitost (glejte poglavje 4.4).
In patients with HCV RNA between 100 IU/ml and 1,000 IU/ml at week 12, 2/8 (25%) achieved an SVR.
Med bolniki s koncentracijami HCV RNK med 100 i.e./ml in 1.000 i.e./ml v 12 tednu, sta 2/8 (25%) dosegla SVR.
in patients with hepatic impairment when inducers or inhibitors of CYP3A4 are concurrently administered and after their discontinuation (see section 4.5) and/or if ciclosporin dosing is markedly reduced or discontinued, as these populations are most likely to have special dosing requirements.
pri bolnikih z okvaro jeter; kadar se sočasno uporabljajo induktorji ali zaviralci CYP3A4 in po njihovi ukinitvi (glejte poglavje 4.5) in/ali če odmerjanje ciklosporina znatno zmanjšamo ali prekinemo, ker je pri teh bolnikih najbolj verjetno, da bodo imeli posebne zahteve glede odmerjanja.
In patients with hepatic impairment, exposures were elevated by 9 to 25%.
Pri bolnikih z okvaro jeter je bila izpostavljenost za 9 do 25 % večja.
In patients with hepatic or renal impairment insulin requirements may be diminished.
Pri bolnikih z okvaro jeter ali ledvic utegnejo biti potrebe po insulinu zmanjšane.
In patients with heterozygous familial hypercholesterolemia (HeFH) on high dose statin, the systemic exposure of evolocumab was slightly lower than in subjects on low-to-moderate dose statin (the ratio of AUClast 0.74 [90%CI 0.29 ; 1.9]).
Pri bolnikih s heterozigotno družinsko hiperholesterolemijo (HeDH), ki so prejemali visokoodmerni statin, je bila sistemska izpostavljenost evolokumabu nekoliko manjša kot pri preiskovancih, ki s prejemali nizek ali zmeren odmerek statina (razmerje AUClast 0,74 [90 % IZ 0,29, 1,9]).
In patients with hidradenitis suppurativa, a dose of 160 mg Humira on Week 0 followed by 80 mg on Week 2 achieved serum adalimumab trough concentrations of approximately 7 to 8 μg/mL at Week 2 and Week 4.
Pri bolnikih s hidradenitis suppurativa doseže odmerek 160 mg zdravila Humira na 0. teden, ki mu sledi 80 mg zdravila Humira 2. teden, najnižjo koncentracijo adalimubaba v serumu pred naslednjim odmerkom približno 7 do 8 g/ml v 2. tednu in v 4. tednu.
In patients with high levels of inhibitor, factor IX therapy may not be effective and other therapeutic options should be considered.
Pri bolnikih z visokimi ravnmi inhibitorja zdravljenje s faktorjem IX morda ne bo učinkovito in bo treba razmisliti o drugih možnostih zdravljenja.
In patients with high levels of inhibitor, factor VIII substitution therapy may not be effective and other therapeutic options should be considered.
Pri bolnikih z veliko koncentracijo zaviralca nadomestno zdravljenje s faktorjem VIII morda ne bo učinkovito, zato je treba razmisliti o drugih možnostih zdravljenja.
In patients with high levels of inhibitor, factor VIII therapy may not be effective and other therapeutic options should be considered.
Pri bolnikih z visokimi ravnmi inhibitorja zdravljenje s faktorjem VIII morda ne bo učinkovito, zato je treba razmisliti o drugih možnostih zdravljenja.
In patients with high levels of inhibitor, factor VIII therapy may not be effective and other therapeutic options should be considered.
Pri bolnikih z visokimi vrednostmi inhibitorjev morda zdravljenje s faktorjem VIII ne bo učinkovito in bo treba razmisliti o drugih možnostih zdravljenja.
In patients with high levels of inhibitor, factor VIII therapy may not be effective and other therapeutic options should be considered.
Pri bolnikih z visoko ravnijo inhibitorjev morda zdravljenje s faktorjem VIII ne bo učinkovito in bo treba razmisliti o drugih možnostih zdravljenja.
In patients with high levels of inhibitor, factor VIII therapy may not be effective and other therapeutic options, such as immune tolerance induction (ITI), should be considered.
Pri bolnikih z visoko ravnijo zaviralcev zdravljenje s faktorjem VIII morda ne bo učinkovito in bo treba premisliti o drugih možnostih zdravljenja, npr. indukciji imunske tolerance (IIT).
In patients with high levels of inhibitor, therapy may not only be ineffective but also lead to anaphylactoid reactions and other therapeutic options should be considered.
Pri bolnikih z visoko ravnijo inhibitorja zdravljenje ne bo le neučinkovito temveč lahko vodi tudi do anafilaktoidnih reakcij in je treba razmisliti o drugih možnostih zdravljenja.
In patients with high titres of inhibitor, factor VIII therapy may not be effective and other therapeutic options should be considered.
Pri bolnikih z visokimi titri inhibitorja, zdravljenje s faktorjem VIII morda ne bo učinkovito, zato je treba razmisliti o drugih možnostih zdravljenja.
In patients with high tumour burden, corresponding figures were 16/81 (20%) and 2/28 (7%) (see section 4.4).
Pri bolnikih z velikim tumorskim bremenom sta bili ustrezni številki 16/81 (20 %) in 2/28 (7 %) (glejte poglavje 4.4).
In patients with HIV
Pri bolnikih s HIV
In patients with HIV
Pri bolnikih, okuženih s HIV
In patients with HIV
Pri bolnikih, okuženih z virusom HIV
In patients with HIV infection For reversal of neutropenia
Pri bolnikih, okuženih s HIV Zaustavitev napredovanja nevtropenije
In patients with hypergammaglobulinemia, normalization of IgG levels was observed by Week 52 in 49% and 20% of patients receiving Benlysta and placebo, respectively.
Pri bolnikih s hipergamaglobulinemijo so normalizacijo koncentracije IgG do 52. tedna ugotovili pri 49 % prejemnikov zdravila Benlysta in pri 20 % prejemnikov placeba.
In patients with impaired hepatic function, atosiban should be used with caution (see sections 4.2 and 4.4).
Pri bolnicah z okvaro delovanja jeter je treba atosiban uporabljati previdno (glejte poglavji 4.2 in 4,4).
In patients with impaired liver function, lactate clearance may be restricted.
Pri bolnikih z okvarjenim delovanjem jeter je očistek laktata lahko zmanjšan.
In patients with impaired renal function (stages 2 to 4 according to the international classification of chronic kidney disease, i.e. creatinine clearance between 15 and 89 ml/min), Cmax and AUC tended to be increased by a factor of 2.5 without any impact on half-life (see section 4.2).
Pri bolnikih z okvarjenim delovanjem ledvic (stadij 2 do 4 po mednarodni klasifikaciji kronične bolezni ledvic, tj. očistek kreatinina med 15 in 89 ml/min) sta bili Cmaks in AUC povečani za 2,5-krat, kar pa ni vplivalo na razpolovni čas (glejte poglavje 4.2).
In patients with impaired renal function, imatinib plasma exposure seems to be higher than that in patients with normal renal function, probably due to an elevated plasma level of alpha-acid glycoprotein (AGP), an imatinib-binding protein, in these patients.
Kaže, da je pri bolnikih z okvarjenim delovanjem ledvic izpostavljenost imatinibu v plazmi višja kot pri bolnikih z normalnim delovanjem ledvic, verjetno zato, ker je pri teh bolnikih zvišana vrednost alfa kislega glikoproteina (AGP – alpha-acid glycoprotein) v plazmi, proteina, ki veže imatinib.
In patients with inhibitor titres above 10 BU or with high anamnestic response, the use of (activated) prothrombin complex concentrate (PCC) or recombinant activated factor VII (rFVIIa) preparations has to be considered.
Pri bolnikih s titrom inhibitorja nad 10 BE ali pozitivno anamnezo je treba razmisliti o uporabi (aktiviranega) koncentrata protrombinskega kompleksa (PCC) ali zdravili z aktiviranim rekombinantnim faktorjem VII (rFVIIa).
In patients with known bone marrow-infiltrating infections or malignancy, consider appropriate therapy for treatment of the underlying condition in addition to administration of filgrastim for treatment of neutropenia.
Pri bolnikih z znano infiltracijo okužbe ali malignim obolenjem v kostni mozeg je treba poleg filgrastima, za zdravljenje nevtropenije, uporabiti še primerno zdravljenje osnovne bolezni.
In patients with known complete absence of dihydropyrimidine dehydrogenase (DPD) activity (see section 4.4),
Pri bolnikih z znano popolno odsotnostjo aktivnosti dihidropirimidin dehidrogenaze (DPD) (glejte poglavje 4.4).
In patients with known dihydropyrimidine dehydrogenase (DPD) deficiency (see section 4.4).
Znano pomanjkanje dihidropirimidin dehidrogenaze (DPD) (glejte poglavje 4.4).
In patients with known predisposing risk factors for iritis/uveitis, travoprost can be used with caution.
Pri bolnikih z znanimi predispozicijskimi dejavniki tveganja za nastanek iritisa ali uveitisa lahko previdno uporabljate travoprost.
In patients with liver scarring, Exviera treatment in combination with Viekirax and ribavirin resulted in a clearance rate of between 93% and 100% after 24 weeks of treatment.
Pri bolnikih s cirozo jeter, ki so prejemali zdravilo Exviera v kombinaciji z zdravilom Viekirax in ribavirinom, je bil po 24 tednih zdravljenja virus odstranjen pri 93–100 % bolnikov.
In patients with liver scarring, Viekirax treatment in combination with dasabuvir and ribavirin resulted in a clearance rate of between 93% and 100% after 24 weeks of treatment.
Pri bolnikih s cirozo jeter, ki so prejemali zdravilo Viekirax v kombinaciji z dasabuvirjem in ribavirinom, je bil po 24 tednih zdravljenja virus odstranjen pri 93–100 % bolnikov.
In patients with long-term stable angina, Corlentor was more effective than placebo at improving exercise capacity and was as effective as atenolol and amlodipine.
Pri bolnikih s kronično stabilno angino pektoris je bilo zdravilo Corlentor pri izboljšanju vadbene zmogljivosti učinkovitejše od placeba in enako učinkovito kot atenolol in amlodipin.
In patients with long-term stable angina, Procoralan was more effective than placebo at improving exercise capacity and was as effective as atenolol and amlodipine.
Pri bolnikih s kronično stabilno angino pektoris je bilo zdravilo Procoralan pri izboljšanju vadbene zmogljivosti učinkovitejše od placeba in enako učinkovito kot atenolol in amlodipin.
In patients with low albumin levels (≤ 35 g/L) or MELD score ≥ 10 at baseline, there was a three-fold greater risk of hepatic decompensation and an increase in the risk of a fatal adverse event compared to those with less advanced liver disease.
Pri bolnikih z nizko vrednostjo albuminov ≤ 35 g/L ali z oceno po MELD ≥ 10 v izhodišču, je bilo tveganje za jetrno dekompenzacijo trikrat večje in povečano tveganje za neželene učinke s smrtnim izidom v primerjavi s tistimi bolniki z manj napredovalo jetrno boleznijo.
In patients with low haemoglobin levels before initiating therapy, there is an increased risk of anaemia during treatment with AVAGLIM.
Pri bolnikih, ki imajo pred začetkom zdravljenja nizek hemoglobin, obstaja med zdravljenjem z AVAGLIMOM večje tveganje za anemijo.
In patients with low systemic blood pressure and in patients with postural hypotension or receiving medicinal products known to reduce blood pressure levels, care should be taken to avoid further hypotension.
Pri bolnikih z nizkim sistemskim krvnim tlakom, bolnikih s posturalno hipotenzijo ali bolnikih, ki jemljejo zdravila, za katere je znano, da znižujejo krvni tlak, je treba paziti, da ne bi prišlo do dodatnega znižanja krvnega tlaka.
In patients with lower body weights (<59 kg, the lowest body weight quartile) the fixed dose used in the Herceptin subcutaneous arm was not associated with an increased risk of cardiac events or significant drop in LVEF.
Pri bolnikih z manjšo telesno maso (< 59 kg, najnižji kvartil telesnih mas) fiksni odmerek uporabljen v skupini, ki je prejemala subkutano obliko zdravila Herceptin, ni bil povezan z višjim tveganjem za neželene učinke, povezane s srcem, ali pomembnim padcem v LVEF.